6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Perforations	NNS	perforations	perforation	perfor	N	B-AdverseReaction
and	CC	and	and	and	N	O
Fistula	NNP	fistula	fistula	fistula	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
[	MD	[	[	[	N	O
see	VB	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
Events	NNS	events	event	event	N	I-AdverseReaction
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Wound	IN	wound	wound	wound	Y	B-AdverseReaction
Complications	NNP	complications	complication	complic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
Jaw	NNP	jaw	jaw	jaw	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Palmar	NNP	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	VBZ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	JJ	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Proteinuria	NNP	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Reversible	JJ	reversible	reversible	revers	N	B-AdverseReaction
Posterior	NNP	posterior	posterior	posterior	N	I-AdverseReaction
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
palmar	SYM	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
hair	NN	hair	hair	hair	N	B-AdverseReaction
color	NN	color	color	color	N	I-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
,	,	,	,	,	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
,	,	,	,	,	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Exelixis	NNP	exelixis	exelixis	exelixi	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
855	CD	855	855	855	N	O
-	:	-	-	-	N	O
500	CD	500	500	500	N	O
-	:	-	-	-	N	O
3935	CD	3935	3935	3935	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
330	CD	330	330	330	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
progressive	JJ	progressive	progressive	progress	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
medullary	JJ	medullary	medullary	medullari	N	O
thyroid	NN	thyroid	thyroid	thyroid	N	O
cancer	NN	cancer	cancer	cancer	Y	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
140	CD	140	140	140	N	O
mg	NN	mg	mg	mg	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
214	CD	214	214	214	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
109	CD	109	109	109	N	O
)	)	)	)	)	N	O
administered	VBD	administered	administered	administ	N	O
daily	RB	daily	daily	daili	N	O
until	IN	until	until	until	N	O
disease	JJ	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
or	CC	or	or	or	N	O
intolerable	JJ	intolerable	intolerable	intoler	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
doubleblind	NN	doubleblind	doubleblind	doubleblind	N	O
,	,	,	,	,	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
See	NNP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
]	NN	]	]	]	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
for	IN	for	for	for	N	O
204	CD	204	204	204	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
exposed	VBD	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
was	VBD	was	wa	wa	N	O
70%	CD	70%	70%	70%	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
90%	CD	90%	90%	90%	N	O
white	JJ	white	white	white	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
55	CD	55	55	55	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Adverse	NNP	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
25%	CD	25%	25%	25%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
occurring	VBG	occurring	occurring	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
arm	NN	arm	arm	arm	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
between	IN	between	between	between	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
difference	NN	difference	difference	differ	N	O
of	IN	of	of	of	N	O
5%	CD	5%	5%	5%	N	O
included	VBD	included	included	includ	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
:	:	:	:	:	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
palmar	SYM	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
hair	NN	hair	hair	hair	N	B-AdverseReaction
color	NN	color	color	color	N	I-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
,	,	,	,	,	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
ALP	NNP	alp	alp	alp	N	I-AdverseReaction
,	,	,	,	,	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypophosphatemia	NN	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
occurring	VBG	occurring	occurring	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
arm	NN	arm	arm	arm	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
between	IN	between	between	between	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
difference	NN	difference	difference	differ	N	O
of	IN	of	of	of	N	O
2%	CD	2%	2%	2%	N	O
included	VBD	included	included	includ	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
frequency	NN	frequency	frequency	frequenc	N	O
;	:	;	;	;	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
,	,	,	,	,	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
weight	NN	weight	weight	weight	Y	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
Table	NNP	table	table	tabl	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
and	CC	and	and	and	N	O
resulted	VBD	resulted	resulted	result	N	O
from	IN	from	from	from	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
septicemia	NN	septicemia	septicemia	septicemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fistulas	NNS	fistulas	fistula	fistula	N	B-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
arrest	NN	arrest	arrest	arrest	N	I-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
unspecified	JJ	unspecified	unspecified	unspecifi	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
and	CC	and	and	and	N	O
resulted	VBD	resulted	resulted	result	N	O
from	IN	from	from	from	N	O
septicemia	NN	septicemia	septicemia	septicemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
general	JJ	general	general	gener	N	B-AdverseReaction
deterioration	NN	deterioration	deterioration	deterior	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
was	VBD	was	wa	wa	N	O
reduced	VBN	reduced	reduced	reduc	N	O
in	IN	in	in	in	N	O
79%	CD	79%	79%	79%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
dosing	VBG	dosing	dosing	dose	N	O
delays	NNS	delays	delay	delay	N	O
was	VBD	was	wa	wa	N	O
one	CD	one	one	one	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
lipase	NN	lipase	lipase	lipas	Y	I-AdverseReaction
,	,	,	,	,	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
tracheal	JJ	tracheal	tracheal	tracheal	N	B-AdverseReaction
fistula	NN	fistula	fistula	fistula	Y	I-AdverseReaction
formation	NN	formation	formation	format	N	I-AdverseReaction
and	CC	and	and	and	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
.	.	.	.	.	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
thyroid	NN	thyroid	thyroid	thyroid	N	I-AdverseReaction
stimulating	VBG	stimulating	stimulating	stimul	N	I-AdverseReaction
hormone	NN	hormone	hormone	hormon	N	I-AdverseReaction
(	(	(	(	(	N	O
TSH	NNP	tsh	tsh	tsh	Y	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
57%	CD	57%	57%	57%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
19%	CD	19%	19%	19%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
baseline	NN	baseline	baseline	baselin	N	O
value	NN	value	value	valu	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Ninety	NNP	ninety	ninety	nineti	N	O
-	:	-	-	-	N	O
two	CD	two	two	two	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
92%	CD	92%	92%	92%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
arm	NN	arm	arm	arm	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
thyroidectomy	NN	thyroidectomy	thyroidectomy	thyroidectomi	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
89%	CD	89%	89%	89%	N	O
were	VBD	were	were	were	N	O
taking	VBG	taking	taking	take	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
Per	NNP	per	per	per	N	O
-	:	-	-	-	N	O
Patient	JJ	patient	patient	patient	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Selected	NNP	selected	selected	select	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Protocol	NNP	protocol	protocol	protocol	N	O
XL184	NNP	xl184	xl184	xl184	N	O
-	:	-	-	-	N	O
301	CD	301	301	301	N	O
Occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNPS	patients	patient	patient	N	O
[	NN	[	[	[	N	O
Between	NNP	between	between	between	N	O
Arm	NNP	arm	arm	arm	N	O
Difference	NNP	difference	difference	differ	N	O
of	IN	of	of	of	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
National	NNP	national	national	nation	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O
Institute	NNP	institute	institute	institut	N	O
Common	NNP	common	common	common	N	O
Terminology	NNP	terminology	terminology	terminolog	N	O
Criteria	NNP	criteria	criterion	criteria	N	O
for	IN	for	for	for	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Events	NNP	events	event	event	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)]	NN	)]	)]	)]	N	O

MedDRA	NNP	meddra	meddra	meddra	N	O
System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Terms	NNS	terms	term	term	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
214	CD	214	214	214	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
109	CD	109	109	109	N	O
)	)	)	)	)	N	O

AllGrades	NNP	allgrades	allgrades	allgrad	N	O
Grades3	NNP	grades3	grades3	grades3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
AllGrades	NNP	allgrades	allgrades	allgrad	N	O
Grades3	NNP	grades3	grades3	grades3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O

GASTROINTESTINAL	NN	gastrointestinal	gastrointestinal	gastrointestin	N	O

DISORDERS	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
63	CD	63	63	63	N	O
16	CD	16	16	16	N	O
33	CD	33	33	33	N	O
2	CD	2	2	2	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
51	CD	51	51	51	N	O
5	CD	5	5	5	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
43	CD	43	43	43	N	O
1	CD	1	1	1	N	O
21	CD	21	21	21	N	O
0	CD	0	0	0	N	O

Oral	NNP	oral	oral	oral	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
36	CD	36	36	36	N	O
2	CD	2	2	2	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
27	CD	27	27	27	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
27	CD	27	27	27	N	O
3	CD	3	3	3	N	O
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
24	CD	24	24	24	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

Dysphagia	NNP	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
4	CD	4	4	4	N	O
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Hemorrhoids	NNS	hemorrhoids	hemorrhoid	hemorrhoid	Y	B-AdverseReaction
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

GENERAL	NNP	general	general	gener	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O
AND	NNP	and	and	and	N	O
ADMINISTRATION	NNP	administration	administration	administr	N	O
SITE	NNP	site	site	site	N	O
CONDITIONS	NNP	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
41	CD	41	41	41	N	O
9	CD	9	9	9	N	O
28	CD	28	28	28	N	O
3	CD	3	3	3	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
21	CD	21	21	21	N	O
6	CD	6	6	6	N	O
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O

INVESTIGATIONS	NN	investigations	investigation	investig	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
weight	VBD	weight	weight	weight	Y	I-AdverseReaction
48	CD	48	48	48	N	O
5	CD	5	5	5	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

METABOLISM	NNP	metabolism	metabolism	metabol	N	O
AND	CC	and	and	and	N	O
NUTRITION	NNP	nutrition	nutrition	nutrit	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
46	CD	46	46	46	N	O
5	CD	5	5	5	N	O
16	CD	16	16	16	N	O
1	CD	1	1	1	N	O

Dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
7	CD	7	7	7	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O

MUSCULOSKELETAL	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
AND	NNP	and	and	and	N	O
CONNECTIVE	NNP	connective	connective	connect	N	O
TISSUE	NNP	tissue	tissue	tissu	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
chest	NN	chest	chest	chest	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
9	CD	9	9	9	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

NERVOUS	NNP	nervous	nervous	nervou	Y	O
SYSTEM	NNP	system	system	system	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
34	CD	34	34	34	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
18	CD	18	18	18	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O

Paresthesia	NNP	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	VBD	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

PSYCHIATRIC	NN	psychiatric	psychiatric	psychiatr	N	O
DISORDERS	NNS	disorders	disorder	disord	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

RESPIRATORY	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
THORACIC	NNP	thoracic	thoracic	thorac	N	O
AND	NNP	and	and	and	N	O
MEDIASTINAL	NNP	mediastinal	mediastinal	mediastin	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Dysphonia	NNP	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
20	CD	20	20	20	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

SKIN	NNP	skin	skin	skin	N	O
AND	NNP	and	and	and	N	O
SUBCUTANEOUS	NNP	subcutaneous	subcutaneous	subcutan	N	O
TISSUE	NNP	tissue	tissue	tissu	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
50	CD	50	50	50	N	O
13	CD	13	13	13	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Hair	NNP	hair	hair	hair	N	B-AdverseReaction
color	NN	color	color	color	N	I-AdverseReaction
changes	NNS	changes	change	chang	N	I-AdverseReaction
depigmentation	NN	depigmentation	depigmentation	depigment	N	I-AdverseReaction
,	,	,	,	,	N	O
graying	VBG	graying	graying	gray	N	I-AdverseReaction
34	CD	34	34	34	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	VBD	skin	skin	skin	N	I-AdverseReaction
19	CD	19	19	19	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
0	CD	0	0	0	N	O

Alopecia	NNP	alopecia	alopecia	alopecia	Y	B-AdverseReaction
16	CD	16	16	16	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Erythema	NNP	erythema	erythema	erythema	Y	B-AdverseReaction
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Hyperkeratosis	$	hyperkeratosis	hyperkeratosis	hyperkeratosi	Y	B-AdverseReaction
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

VASCULAR	NNP	vascular	vascular	vascular	N	O
DISORDERS	NNS	disorders	disorder	disord	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
33	CD	33	33	33	N	O
8	CD	8	8	8	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Hypotension	NNP	hypotension	hypotension	hypotens	Y	B-AdverseReaction
7	CD	7	7	7	N	O
1	CD	1	1	1	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Percent	NNP	percent	percent	percent	N	O
-	:	-	-	-	N	O
Patient	JJ	patient	patient	patient	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Occurring	NNP	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Protocol	NNP	protocol	protocol	protocol	N	O
XL184	NNP	xl184	xl184	xl184	N	O
-	:	-	-	-	N	O
301	CD	301	301	301	N	O
[	NN	[	[	[	N	O
Between	NNP	between	between	between	N	O
Arm	NNP	arm	arm	arm	N	O
Difference	NNP	difference	difference	differ	N	O
of	IN	of	of	of	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)]	NN	)]	)]	)]	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Event	NNP	event	event	event	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
214	CD	214	214	214	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
109	CD	109	109	109	N	O
)	)	)	)	)	N	O

AllGrades	NNP	allgrades	allgrades	allgrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
AllGrades	NNP	allgrades	allgrades	allgrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O

Chemistries	NNS	chemistries	chemistry	chemistri	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction

AST	$	ast	ast	ast	N	I-AdverseReaction
86	CD	86	86	86	N	O
3	CD	3	3	3	N	O
35	CD	35	35	35	N	O
2	CD	2	2	2	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
86	CD	86	86	86	N	O
6	CD	6	6	6	N	O
41	CD	41	41	41	N	O
2	CD	2	2	2	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
ALP	NNP	alp	alp	alp	N	I-AdverseReaction
52	CD	52	52	52	N	O
3	CD	3	3	3	N	O
35	CD	35	35	35	N	O
3	CD	3	3	3	N	O

Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
52	CD	52	52	52	N	O
12	CD	12	12	12	N	O
27	CD	27	27	27	N	O
3	CD	3	3	3	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
28	CD	28	28	28	N	O
3	CD	3	3	3	N	O
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O

Hyperbilirubinemia	NNP	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
25	CD	25	25	25	N	O
2	CD	2	2	2	N	O
14	CD	14	14	14	N	O
5	CD	5	5	5	N	O

Hypomagnesemia	NNP	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
18	CD	18	18	18	N	O
4	CD	4	4	4	N	O
9	CD	9	9	9	N	O
3	CD	3	3	3	N	O

Hyponatremia	NNP	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
2	CD	2	2	2	N	O
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Hematologic	NN	hematologic	hematologic	hematolog	N	O

Lymphopenia	NNP	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
53	CD	53	53	53	N	O
16	CD	16	16	16	N	O
51	CD	51	51	51	N	O
11	CD	11	11	11	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
35	CD	35	35	35	N	O
3	CD	3	3	3	N	O
15	CD	15	15	15	N	O
2	CD	2	2	2	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
35	CD	35	35	35	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O

ALT	NN	alt	alt	alt	N	O

,	,	,	,	,	N	O
alanine	JJ	alanine	alanine	alanin	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
;	:	;	;	;	N	O
ALP	NNP	alp	alp	alp	N	O
,	,	,	,	,	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	O
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	O
;	:	;	;	;	N	O
AST	NNP	ast	ast	ast	N	O
,	,	,	,	,	N	O
aspartate	NN	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O

Nearly	RB	nearly	nearly	nearli	N	O
all	DT	all	all	all	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
96%	CD	96%	96%	96%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

84%	CD	84%	84%	84%	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
and	CC	and	and	and	N	O
there	EX	there	there	there	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
doubling	NN	doubling	doubling	doubl	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
overt	JJ	overt	overt	overt	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
in	IN	in	in	in	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
over	IN	over	over	over	N	O
placebo	JJ	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
61%	CD	61%	61%	61%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
modified	VBN	modified	modified	modifi	N	O
Joint	NNP	joint	joint	joint	N	O
National	NNP	national	national	nation	N	O
Committee	NNP	committee	committee	committe	N	O
on	IN	on	on	on	N	O
Prevention	NNP	prevention	prevention	prevent	Y	O
,	,	,	,	,	N	O
Detection	NNP	detection	detection	detect	N	O
,	,	,	,	,	N	O
Evaluation	NNP	evaluation	evaluation	evalu	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
High	NNP	high	high	high	N	O
Blood	NNP	blood	blood	blood	N	O
Pressure	NNP	pressure	pressure	pressur	N	O
(	(	(	(	(	N	O
JNC	NNP	jnc	jnc	jnc	N	O
)	)	)	)	)	N	O
staging	VBG	staging	staging	stage	N	O
criteria	NNS	criteria	criterion	criteria	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
malignant	JJ	malignant	malignant	malign	N	B-AdverseReaction
hypertension	NN	hypertension	hypertension	hypertens	Y	I-AdverseReaction
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

3	CD	3	3	3	N	O
Per	NNP	per	per	per	N	O
-	:	-	-	-	N	O
Patient	JJ	patient	patient	patient	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
in	IN	in	in	in	N	O
Protocol	NNP	protocol	protocol	protocol	N	O
XL184	NNP	xl184	xl184	xl184	N	O
-	:	-	-	-	N	O
301	CD	301	301	301	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
JNCStage	NNP	jncstage	jncstage	jncstage	N	O
COMETRIQN	NNP	cometriqn	cometriqn	cometriqn	N	O
211	CD	211	211	211	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
PlaceboN	VBZ	placebon	placebon	placebon	N	O
107	CD	107	107	107	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Normal	JJ	normal	normal	normal	N	O
:	:	:	:	:	N	O
Grade	JJ	grade	grade	grade	N	O
0	CD	0	0	0	N	O
:	:	:	:	:	N	O
Systolic	JJ	systolic	systolic	systol	N	O
120	CD	120	120	120	N	O
mmHg	NN	mmhg	mmhg	mmhg	N	O
and	CC	and	and	and	N	O
Diastolic	NNP	diastolic	diastolic	diastol	N	O
80	CD	80	80	80	N	O
mmHg	VBD	mmhg	mmhg	mmhg	N	O
4	CD	4	4	4	N	O
15	CD	15	15	15	N	O

Pre	NNP	pre	pre	pre	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
hypertension	NN	hypertension	hypertension	hypertens	Y	I-AdverseReaction
:	:	:	:	:	N	O
Systolic	JJ	systolic	systolic	systol	N	B-Severity
120	CD	120	120	120	N	I-Severity
mmHg	NN	mmhg	mmhg	mmhg	N	I-Severity
or	CC	or	or	or	N	O
Diastolic	NNP	diastolic	diastolic	diastol	N	B-Severity
80	CD	80	80	80	N	I-Severity
mmHg	VBD	mmhg	mmhg	mmhg	N	I-Severity
34	CD	34	34	34	N	O
54	CD	54	54	54	N	O

Stage	NN	stage	stage	stage	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Systolic	JJ	systolic	systolic	systol	N	O
140	CD	140	140	140	N	O
mmHg	NN	mmhg	mmhg	mmhg	N	O
or	CC	or	or	or	N	O
Diastolic	NNP	diastolic	diastolic	diastol	N	O
90	CD	90	90	90	N	O
mmHg	VBD	mmhg	mmhg	mmhg	N	O
46	CD	46	46	46	N	O
25	CD	25	25	25	N	O

Stage	NN	stage	stage	stage	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Systolic	JJ	systolic	systolic	systol	N	O
160	CD	160	160	160	N	O
mmHg	NN	mmhg	mmhg	mmhg	N	O
or	CC	or	or	or	N	O
Diastolic	NNP	diastolic	diastolic	diastol	N	O
100	CD	100	100	100	N	O
mmHg	VBD	mmhg	mmhg	mmhg	N	O
15	CD	15	15	15	N	O
5	CD	5	5	5	N	O

Malignant	JJ	malignant	malignant	malign	N	O
:	:	:	:	:	N	O
Diastolic	JJ	diastolic	diastolic	diastol	N	O
120	CD	120	120	120	N	O
mmHg	NN	mmhg	mmhg	mmhg	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
PERFORATIONS	NN	perforations	perforation	perfor	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
FISTULAS	NNP	fistulas	fistula	fistula	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
HEMORRHAGE	NNP	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
\n\n	VBD	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
PERFORATIONS	NN	perforations	perforation	perfor	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
FISTULAS	NNP	fistulas	fistula	fistula	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
HEMORRHAGE	NNP	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Perforations	NNP	perforations	perforation	perfor	N	B-AdverseReaction
and	CC	and	and	and	N	O
fistulas	NNS	fistulas	fistula	fistula	N	B-AdverseReaction
:	:	:	:	:	N	O
Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
perforations	NNS	perforations	perforation	perfor	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
and	CC	and	and	and	N	O
fistula	JJ	fistula	fistula	fistula	Y	B-AdverseReaction
formation	NN	formation	formation	format	N	I-AdverseReaction
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
COMETRIQTM	NNP	cometriqtm	cometriqtm	cometriqtm	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
for	IN	for	for	for	N	O
perforation	NN	perforation	perforation	perfor	Y	O
or	CC	or	or	or	N	O
for	IN	for	for	for	N	O
fistula	JJ	fistula	fistula	fistula	Y	O
formation	NN	formation	formation	format	N	O
[	NNP	[	[	[	N	O
See	NNP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
:	:	:	:	:	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
administer	VB	administer	administer	administ	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O
[	VBD	[	[	[	N	O
See	NNP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
PERFORATIONS	NN	perforations	perforation	perfor	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
FISTULAS	NNP	fistulas	fistula	fistula	N	B-AdverseReaction
,	,	,	,	,	N	O
andHEMORRHAGE	NN	andhemorrhage	andhemorrhage	andhemorrhag	N	B-AdverseReaction
\n\n\n\n	SYM	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Perforations	NNS	perforations	perforation	perfor	N	B-AdverseReaction
and	CC	and	and	and	N	O
Fistulas	NNS	fistulas	fistula	fistula	N	B-AdverseReaction
:	:	:	:	:	N	O
Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
perforations	NNS	perforations	perforation	perfor	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
and	CC	and	and	and	N	O
fistula	JJ	fistula	fistula	fistula	Y	B-AdverseReaction
formation	NN	formation	formation	format	N	I-AdverseReaction
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
perforation	NN	perforation	perforation	perfor	Y	O
or	CC	or	or	or	N	O
fistula	NN	fistula	fistula	fistula	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
:	:	:	:	:	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
administer	VB	administer	administer	administ	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
Events	NNS	events	event	event	N	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
for	IN	for	for	for	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	O
arterial	JJ	arterial	arterial	arteri	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Wound	JJ	wound	wound	wound	Y	B-AdverseReaction
Complications	NNS	complications	complication	complic	N	I-AdverseReaction
:	:	:	:	:	N	O
Withhold	NNP	withhold	withhold	withhold	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
for	IN	for	for	for	N	O
dehiscence	NN	dehiscence	dehiscence	dehisc	N	O
or	CC	or	or	or	N	O
complications	NNS	complications	complication	complic	N	O
requiring	VBG	requiring	requiring	requir	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
for	IN	for	for	for	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
crisis	NN	crisis	crisis	crisi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
jaw	NN	jaw	jaw	jaw	N	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Palmar	NNP	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
Erythrodysesthesia	NNP	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Interrupt	NNP	interrupt	interrupt	interrupt	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
,	,	,	,	,	N	O
decrease	NN	decrease	decrease	decreas	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
urine	JJ	urine	urine	urin	N	O
protein	NN	protein	protein	protein	Y	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
for	IN	for	for	for	N	O
nephrotic	JJ	nephrotic	nephrotic	nephrot	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Reversible	JJ	reversible	reversible	revers	N	B-AdverseReaction
posterior	JJ	posterior	posterior	posterior	N	I-AdverseReaction
leukoencephalopathy	JJ	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
RPLS	NNP	rpls	rpls	rpl	N	B-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Perforations	NNS	perforations	perforation	perfor	N	O

and	CC	and	and	and	N	O
Fistulas	NNP	fistulas	fistula	fistula	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
(	(	(	(	(	N	O
GI	NNP	gi	gi	gi	N	B-AdverseReaction
)	)	)	)	)	N	O
perforations	NNS	perforations	perforation	perfor	N	I-AdverseReaction
and	CC	and	and	and	N	O
fistulas	NNS	fistulas	fistula	fistula	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
were	VBD	were	were	were	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
GI	NNP	gi	gi	gi	N	B-AdverseReaction
fistula	NN	fistula	fistula	fistula	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
GI	NNP	gi	gi	gi	N	I-AdverseReaction
fistulas	NNS	fistulas	fistula	fistula	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
tracheal	JJ	tracheal	tracheal	tracheal	N	I-AdverseReaction
esophageal	NN	esophageal	esophageal	esophag	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
were	VBD	were	were	were	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
perforations	NNS	perforations	perforation	perfor	N	O
and	CC	and	and	and	N	O
fistulas	NNS	fistulas	fistula	fistula	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
a	DT	a	a	a	N	O
perforation	NN	perforation	perforation	perfor	Y	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
fistula	NN	fistula	fistula	fistula	Y	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O

Serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
administer	VB	administer	administer	administ	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
recent	JJ	recent	recent	recent	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O
or	CC	or	or	or	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
Events	NNS	events	event	event	N	O

COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
treatment	NN	treatment	treatment	treatment	N	O
results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
:	:	:	:	:	N	O
6%	CD	6%	6%	6%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

3%	CD	3%	3%	3%	N	O
and	CC	and	and	and	N	O
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	I-AdverseReaction
:	:	:	:	:	N	O
2%	CD	2%	2%	2%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

0%	CD	0%	0%	0%	N	O
in	IN	in	in	in	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
and	CC	and	and	and	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
an	DT	an	an	an	N	O
acute	JJ	acute	acute	acut	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
arterial	JJ	arterial	arterial	arteri	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
complication	NN	complication	complication	complic	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Wound	NNP	wound	wound	wound	Y	O
Complications	NNS	complications	complication	complic	N	O

Wound	IN	wound	wound	wound	Y	B-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
.	.	.	.	.	N	O

Stop	NNP	stop	stop	stop	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
28	CD	28	28	28	N	O
days	NNS	days	day	day	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
scheduled	VBN	scheduled	scheduled	schedul	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
.	.	.	.	.	N	O

Resume	NNP	resume	resume	resum	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
therapy	NN	therapy	therapy	therapi	N	O
after	IN	after	after	after	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
clinical	JJ	clinical	clinical	clinic	N	O
judgment	NN	judgment	judgment	judgment	N	O
of	IN	of	of	of	N	O
adequate	JJ	adequate	adequate	adequ	N	O
wound	NN	wound	wound	wound	Y	O
healing	NN	healing	healing	heal	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
dehiscence	NN	dehiscence	dehiscence	dehisc	N	O
or	CC	or	or	or	N	O
wound	NN	wound	wound	wound	Y	O
healing	NN	healing	healing	heal	N	O
complications	NNS	complications	complication	complic	N	O
requiring	VBG	requiring	requiring	requir	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Hypertension	NN	hypertension	hypertension	hypertens	Y	O

COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
treatment	NN	treatment	treatment	treatment	N	O
results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
with	IN	with	with	with	N	O
Joint	NNP	joint	joint	joint	N	O
National	NNP	national	national	nation	N	O
Committee	NNP	committee	committee	committe	N	O
on	IN	on	on	on	N	O
Prevention	NNP	prevention	prevention	prevent	Y	O
,	,	,	,	,	N	O
Detection	NNP	detection	detection	detect	N	O
,	,	,	,	,	N	O
Evaluation	NNP	evaluation	evaluation	evalu	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
High	NNP	high	high	high	N	O
Blood	NNP	blood	blood	blood	N	O
Pressure	NNP	pressure	pressure	pressur	N	O
(	(	(	(	(	N	O
modified	VBN	modified	modified	modifi	N	O
JNC	NNP	jnc	jnc	jnc	N	O
criteria	NNS	criteria	criterion	criteria	N	O
)	)	)	)	)	N	O
stage	VBP	stage	stage	stage	N	B-Severity
1	CD	1	1	1	N	I-Severity
or	CC	or	or	or	N	O
2	CD	2	2	2	N	I-Severity
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
identified	VBN	identified	identified	identifi	N	O
in	IN	in	in	in	N	O
61%	CD	61%	61%	61%	N	O
in	IN	in	in	in	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
30%	CD	30%	30%	30%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
and	CC	and	and	and	N	O
regularly	RB	regularly	regularly	regularli	N	O
during	IN	during	during	dure	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
for	IN	for	for	for	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
adequately	RB	adequately	adequately	adequ	N	O
controlled	VBN	controlled	controlled	control	N	O
with	IN	with	with	with	N	O
medical	JJ	medical	medical	medic	N	O
management	NN	management	management	manag	N	O
;	:	;	;	;	N	O
when	WRB	when	when	when	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
resume	VB	resume	resume	resum	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
that	IN	that	that	that	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
controlled	VBN	controlled	controlled	control	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Jaw	NNP	jaw	jaw	jaw	N	O

Osteonecrosis	NN	osteonecrosis	osteonecrosis	osteonecrosi	Y	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
jaw	NN	jaw	jaw	jaw	N	I-AdverseReaction
(	(	(	(	(	N	O
ONJ	NNP	onj	onj	onj	N	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

ONJ	NNP	onj	onj	onj	N	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
manifest	VB	manifest	manifest	manifest	N	O
as	IN	as	a	as	N	O
jaw	NN	jaw	jaw	jaw	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
osteomyelitis	NN	osteomyelitis	osteomyelitis	osteomyel	Y	B-AdverseReaction
,	,	,	,	,	N	O
osteitis	NN	osteitis	osteitis	osteiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
erosion	NN	erosion	erosion	eros	N	I-AdverseReaction
,	,	,	,	,	N	O
tooth	CC	tooth	tooth	tooth	N	B-AdverseReaction
or	CC	or	or	or	N	O
periodontal	JJ	periodontal	periodontal	periodont	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
toothache	NN	toothache	toothache	toothach	Y	B-AdverseReaction
,	,	,	,	,	N	O
gingival	JJ	gingival	gingival	gingiv	N	B-AdverseReaction
ulceration	NN	ulceration	ulceration	ulcer	N	I-AdverseReaction
or	CC	or	or	or	N	O
erosion	NN	erosion	erosion	eros	N	I-AdverseReaction
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	B-AdverseReaction
jaw	NN	jaw	jaw	jaw	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
or	CC	or	or	or	N	O
slow	VB	slow	slow	slow	N	B-AdverseReaction
healing	NN	healing	healing	heal	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
or	CC	or	or	or	N	O
jaw	NN	jaw	jaw	jaw	N	I-AdverseReaction
after	IN	after	after	after	N	I-AdverseReaction
dental	JJ	dental	dental	dental	N	I-AdverseReaction
surgery	NN	surgery	surgery	surgeri	Y	I-AdverseReaction
.	.	.	.	.	N	O

Perform	VB	perform	perform	perform	N	O
an	DT	an	an	an	N	O
oral	JJ	oral	oral	oral	N	O
examination	NN	examination	examination	examin	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
regarding	VBG	regarding	regarding	regard	N	O
good	JJ	good	good	good	N	O
oral	JJ	oral	oral	oral	N	O
hygiene	NN	hygiene	hygiene	hygien	N	O
practices	NNS	practices	practice	practic	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
invasive	JJ	invasive	invasive	invas	N	O
dental	NN	dental	dental	dental	N	O
procedures	NNS	procedures	procedure	procedur	N	O
,	,	,	,	,	N	O
withhold	VBD	withhold	withhold	withhold	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
28	CD	28	28	28	N	O
days	NNS	days	day	day	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
scheduled	VBN	scheduled	scheduled	schedul	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
possible	JJ	possible	possible	possibl	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Palmar	NNP	palmar	palmar	palmar	N	O
-	:	-	-	-	N	O
Plantar	NNP	plantar	plantar	plantar	N	O
Erythrodysesthesia	NNP	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Palmar	NNP	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	JJ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
PPES	NNP	ppes	ppes	ppe	N	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
50%	CD	50%	50%	50%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
and	CC	and	and	and	N	O
was	VBD	was	wa	wa	N	O
severe	JJ	severe	severe	sever	N	B-Severity
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
13%	CD	13%	13%	13%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
intolerable	JJ	intolerable	intolerable	intoler	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
PPES	NNP	ppes	ppes	ppe	N	O
or	CC	or	or	or	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
PPES	NNP	ppes	ppes	ppe	N	O
until	IN	until	until	until	N	O
improvement	NN	improvement	improvement	improv	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
1	CD	1	1	1	N	O
;	:	;	;	;	N	O
resume	VB	resume	resume	resum	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
reduced	JJ	reduced	reduced	reduc	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	O

Proteinuria	NNP	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
one	CD	one	one	one	N	O
with	IN	with	with	with	N	O
nephrotic	JJ	nephrotic	nephrotic	nephrot	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
urine	JJ	urine	urine	urin	N	O
protein	NN	protein	protein	protein	Y	O
regularly	RB	regularly	regularly	regularli	N	O
during	IN	during	during	dure	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
nephrotic	JJ	nephrotic	nephrotic	nephrot	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Reversible	JJ	reversible	reversible	revers	N	O
Posterior	NNP	posterior	posterior	posterior	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Reversible	JJ	reversible	reversible	revers	N	B-AdverseReaction
Posterior	NNP	posterior	posterior	posterior	N	I-AdverseReaction
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
RPLS	NNP	rpls	rpls	rpl	N	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
of	IN	of	of	of	N	O
subcortical	JJ	subcortical	subcortical	subcort	N	B-AdverseReaction
vasogenic	JJ	vasogenic	vasogenic	vasogen	N	I-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
diagnosed	VBN	diagnosed	diagnosed	diagnos	N	O
by	IN	by	by	by	N	O
characteristic	JJ	characteristic	characteristic	characterist	N	O
finding	NN	finding	finding	find	N	O
on	IN	on	on	on	N	O
MRI	NNP	mri	mri	mri	Y	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

Perform	VB	perform	perform	perform	N	O
an	DT	an	an	an	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
for	IN	for	for	for	N	O
RPLS	NNP	rpls	rpls	rpl	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
patient	JJ	patient	patient	patient	N	O
presenting	NN	presenting	presenting	present	N	O
with	IN	with	with	with	N	O
seizures	NNS	seizures	seizure	seizur	Y	O
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	O
,	,	,	,	,	N	O
visual	JJ	visual	visual	visual	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
,	,	,	,	,	N	O
confusion	NN	confusion	confusion	confus	Y	O
or	CC	or	or	or	N	O
altered	VBN	altered	altered	alter	N	O
mental	JJ	mental	mental	mental	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
RPLS	NNP	rpls	rpls	rpl	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
with	IN	with	with	with	N	O
agents	NNS	agents	agent	agent	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
strong	JJ	strong	strong	strong	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
inducers	NNS	inducers	inducer	induc	N	O
or	CC	or	or	or	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
,	,	,	,	,	N	O
7.2	CD	7.2	7.2	7.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Impairment	NN	impairment	impairment	impair	N	O

COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

COMETRIQ	NNP	cometriq	cometriq	cometriq	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Cabozantinib	NNP	cabozantinib	cabozantinib	cabozantinib	N	O
was	VBD	was	wa	wa	N	O
embryolethal	VBN	embryolethal	embryolethal	embryoleth	N	B-AdverseReaction
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
at	IN	at	at	at	N	O
exposures	NNS	exposures	exposure	exposur	N	O
below	IN	below	below	below	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
human	NN	human	human	human	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
increased	JJ	increased	increased	increas	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
skeletal	JJ	skeletal	skeletal	skelet	N	B-AdverseReaction
variations	NNS	variations	variation	variat	N	I-AdverseReaction
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
and	CC	and	and	and	N	O
visceral	JJ	visceral	visceral	viscer	N	B-AdverseReaction
variations	NNS	variations	variation	variat	N	I-AdverseReaction
and	CC	and	and	and	N	O
malformations	NNS	malformations	malformation	malform	N	I-AdverseReaction
in	IN	in	in	in	N	O
rabbits	NNS	rabbits	rabbit	rabbit	N	B-Animal
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
See	NNP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

